glp-1 eye Doctor Explains GLP 1 Blindness Risk (Should You Be Worried?) GLP-1 Agonists May Lower Risk

The label includes a boxed warning regarding thyroid C-cell tumors based on rodent studies and states that Wegovy should not be used in patients with a personal or family history of medullary thyroid carcinoma or MEN 2

The absence of brain fog from formal adverse event reporting does not definitively exclude its occurrence, as post-marketing surveillance continues to monitor real-world experiences beyond controlled clinical trial settings

(2025) T2DM: 47.3% reinitiated GLP-1 therapy within 1 year of discontinuation 57.3% reinitiated within 2 years Without T2DM: 36.3% reinitiated within 1 year 46.4% reinitiated within 2 years Key Factors Linked to Reinitiation: Patients age 65 years Less likely to reinitiate Weight regain after discontinuation Higher likelihood of restarting therapy Moderate to severe GI side effects during initial treatment Lower likelihood of reinitiation Main Takeaway: Most patients who initiated GLP-1 therapy stopped within one year, with higher discontinuation rates among those without T2DM

Obtaining coverage for Zepbound is limited to its FDA-approved indication

Ozempic (semaglutide): Patients taking the 2.0 mg dose can lower their A1C up to 2.1% in some studies

Adults (2019-2024) Prescription Patterns and Healthcare Provider Trends Advanced practice practitioners and primary care physicians increasingly prescribe these medications, with APPs' share rising from 25.3% to 40.6% between 2017 and 2024 ^22